Literature DB >> 2225095

Cerebral vasospasm.

R H Wilkins1.   

Abstract

Cerebral vasospasm (specifically, intracranial arterial spasm) is variously defined as: (1) an arteriographically evident narrowing of the lumen of one or more of the major intracranial arteries at the base of the brain due to contraction of the smooth muscle within the arterial wall, or due to the morphological changes in the arterial wall and along its endothelial surface that occur in response to vessel injury; (2) the delayed onset of a neurological deficit following subarachnoid hemorrhage, thought to be due to ischemia or infarction of a portion of the brain; or (3) the combination of these two features (symptomatic vasospasm). The arterial contraction of intracranial arterial spasm typically develops a few days after the rupture of an intracranial aneurysm and lasts 2 to 3 weeks. Such arterial spasm can also occur in other conditions such as head trauma. If it is severe enough it can lead to cerebral infarction. The pathogenesis of this condition is still unclear. Many ingenious attempts have been made to prevent or treat cerebral vasospasm, but most have failed. The best current approach is to ensure adequate blood volume, and to elevate the patient's blood pressure (especially if the aneurysm has been secured by an early operation). The continuing investigation of drugs such as calcium channel blocking agents to improve the cerebral circulation has begun to provide additional help.

Entities:  

Mesh:

Year:  1990        PMID: 2225095

Source DB:  PubMed          Journal:  Crit Rev Neurobiol        ISSN: 0892-0915


  18 in total

Review 1.  Vascular plasticity in cerebrovascular disorders.

Authors:  Lars I H Edvinsson; Gro Klitgaard Povlsen
Journal:  J Cereb Blood Flow Metab       Date:  2011-05-11       Impact factor: 6.200

2.  Vascular neural network in subarachnoid hemorrhage.

Authors:  John H Zhang
Journal:  Transl Stroke Res       Date:  2014-07-03       Impact factor: 6.829

Review 3.  Current management of delayed cerebral ischemia: update from results of recent clinical trials.

Authors:  Shakira Brathwaite; R Loch Macdonald
Journal:  Transl Stroke Res       Date:  2013-12-13       Impact factor: 6.829

4.  Controversies and evolving new mechanisms in subarachnoid hemorrhage.

Authors:  Sheng Chen; Hua Feng; Prativa Sherchan; Damon Klebe; Gang Zhao; Xiaochuan Sun; Jianmin Zhang; Jiping Tang; John H Zhang
Journal:  Prog Neurobiol       Date:  2013-09-25       Impact factor: 11.685

5.  Cannabinoid type 2 receptor stimulation attenuates brain edema by reducing cerebral leukocyte infiltration following subarachnoid hemorrhage in rats.

Authors:  Mutsumi Fujii; Prativa Sherchan; Paul R Krafft; William B Rolland; Yoshiteru Soejima; John H Zhang
Journal:  J Neurol Sci       Date:  2014-04-30       Impact factor: 3.181

Review 6.  Early brain injury, an evolving frontier in subarachnoid hemorrhage research.

Authors:  Mutsumi Fujii; Junhao Yan; William B Rolland; Yoshiteru Soejima; Basak Caner; John H Zhang
Journal:  Transl Stroke Res       Date:  2013-08       Impact factor: 6.829

7.  Imatinib preserves blood-brain barrier integrity following experimental subarachnoid hemorrhage in rats.

Authors:  Yan Zhan; Paul R Krafft; Tim Lekic; Qingyi Ma; Rhonda Souvenir; John H Zhang; Jiping Tang
Journal:  J Neurosci Res       Date:  2014-09-04       Impact factor: 4.164

8.  Role of calcitonin gene-related peptide in cerebral vasospasm, and as a therapeutic approach to subarachnoid hemorrhage.

Authors:  Stelios Kokkoris; Peter Andrews; David J Webb
Journal:  Front Endocrinol (Lausanne)       Date:  2012-11-15       Impact factor: 5.555

Review 9.  Subarachnoid hemorrhage and cerebral vasospasm - literature review.

Authors:  A V Ciurea; C Palade; D Voinescu; D A Nica
Journal:  J Med Life       Date:  2013-06-25

10.  Cerebral Microdialysis-Based Interventions Targeting Delayed Cerebral Ischemia Following Aneurysmal Subarachnoid Hemorrhage.

Authors:  Jakob Winberg; Isabella Holm; David Cederberg; Malin Rundgren; Erik Kronvall; Niklas Marklund
Journal:  Neurocrit Care       Date:  2022-04-29       Impact factor: 3.532

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.